Sellas Life Sciences Group, Inc. (SLS) — 8-K Filings

8-K Filings (20)

• SELLAS Life Sciences Group Enters Material Definitive Agreement — Oct 27, 2025 Risk: medium
  On October 24, 2025, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The company, formerly known as Galena Biopharma, Inc. and RX
• SELLAS Life Sciences Group Enters Material Definitive Agreement — Oct 3, 2025 Risk: medium
  On October 1, 2025, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The filing does not provide specific details on the agreement
• SELLAS Life Sciences Group Files 8-K — Sep 11, 2025 Risk: medium
  On September 10, 2025, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity
• SELLAS Life Sciences Group Files 8-K on Security Holder Vote Matters — Jun 18, 2025 Risk: low
  On June 17, 2025, SELLAS Life Sciences Group, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporat
• SELLAS Life Sciences Appoints PricewaterhouseCoopers as New Auditor — Jun 6, 2025 Risk: low
  On June 3, 2025, SELLAS Life Sciences Group, Inc. announced a change in its certifying accountant. The company has appointed PricewaterhouseCoopers LLP as its n
• SELLAS Life Sciences Group Enters Material Definitive Agreement — Jan 29, 2025 Risk: medium
  On January 28, 2025, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The company, previously known as Galena Biopharma, Inc. and
• SELLAS Life Sciences Group Files 8-K — Jan 23, 2025 Risk: low
  On January 23, 2025, SELLAS Life Sciences Group, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and E
• SELLAS Life Sciences Appoints New Director, Director Departs — Jan 16, 2025 Risk: low
  On January 10, 2025, SELLAS Life Sciences Group, Inc. announced changes to its Board of Directors. Dr. Anthony S. Marfione, Jr. resigned from his position as a
• SELLAS Life Sciences Group Files 8-K — Dec 10, 2024 Risk: low
  On December 10, 2024, SELLAS Life Sciences Group, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and
• SELLAS Life Sciences Group Enters Material Definitive Agreement — Oct 4, 2024 Risk: medium
  On October 3, 2024, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement. The filing does not specify the nature of the agreement or an
• SELLAS Life Sciences Secures $50M Financing for GPS Commercialization — Aug 1, 2024 Risk: medium
  On July 30, 2024, SELLAS Life Sciences Group, Inc. entered into a material definitive agreement related to its Galinpepimut-S (GPS) drug. This agreement involve
• SELLAS Life Sciences Group Files 8-K on Shareholder Vote Matters — Jun 21, 2024 Risk: low
  On June 20, 2024, SELLAS Life Sciences Group, Inc. filed an 8-K to report on matters submitted to a vote of its security holders. The filing details the company
• SELLAS Life Sciences Closes $15M Public Offering — Mar 28, 2024 Risk: medium
  On March 28, 2024, SELLAS Life Sciences Group, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully rai
• SELLAS Life Sciences Group Files 8-K — Mar 15, 2024 Risk: medium
  On March 15, 2024, SELLAS Life Sciences Group, Inc. announced a material definitive agreement related to its Galinpepimut-S (GPS) drug. The company also reporte
• SELLAS Life Sciences Closes $20M Public Offering — Mar 11, 2024 Risk: medium
  On March 11, 2024, SELLAS Life Sciences Group, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully rai
• SELLAS Life Sciences Appoints New CMO, Dr. Stergiou — Mar 8, 2024 Risk: medium
  On March 6, 2024, SELLAS Life Sciences Group, Inc. announced the appointment of Dr. Angelos Stergiou as Chief Medical Officer and the resignation of Dr. John "J
• SELLAS Life Sciences Closes $15M Public Offering — Mar 5, 2024 Risk: medium
  On March 5, 2024, SELLAS Life Sciences Group, Inc. announced the closing of its previously disclosed underwritten public offering. The company successfully rais
• SELLAS Life Sciences Faces Nasdaq Delisting Warning — Feb 16, 2024 Risk: high
  SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) received a delisting notice from Nasdaq on February 14, 2024, due to its failure to maintain a minimum bid price
• SELLAS Life Sciences Reports Material Definitive Agreement — Jan 8, 2024
  SELLAS Life Sciences Group, Inc. filed an 8-K on January 8, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that occurred on
• SELLAS Life Sciences Terminates Material Agreement — Jan 3, 2024
  SELLAS Life Sciences Group, Inc. announced on January 2, 2024, the termination of a material definitive agreement. This termination, while not detailing the spe

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX